A detailed history of Smith Chas P & Associates Pa Cpas transactions in Amgen Inc stock. As of the latest transaction made, Smith Chas P & Associates Pa Cpas holds 110,882 shares of AMGN stock, worth $29.3 Million. This represents 2.02% of its overall portfolio holdings.

Number of Shares
110,882
Previous 113,680 2.46%
Holding current value
$29.3 Million
Previous $35.5 Million 0.59%
% of portfolio
2.02%
Previous 2.11%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

SELL
$309.38 - $337.38 $865,645 - $943,989
-2,798 Reduced 2.46%
110,882 $35.7 Million
Q2 2024

Jul 29, 2024

BUY
$262.75 - $319.31 $442,996 - $538,356
1,686 Added 1.51%
113,680 $35.5 Million
Q1 2024

Apr 25, 2024

BUY
$268.87 - $324.56 $848,553 - $1.02 Million
3,156 Added 2.9%
111,994 $31.8 Million
Q4 2023

Feb 01, 2024

BUY
$255.7 - $288.46 $734,626 - $828,745
2,873 Added 2.71%
108,838 $31.3 Million
Q3 2023

Nov 02, 2023

BUY
$218.65 - $271.46 $1.86 Million - $2.31 Million
8,507 Added 8.73%
105,965 $28.5 Million
Q2 2023

Jul 31, 2023

BUY
$214.27 - $253.37 $20.6 Million - $24.4 Million
96,207 Added 7690.41%
97,458 $21.6 Million
Q1 2023

Apr 27, 2023

SELL
$225.79 - $275.2 $11,515 - $14,035
-51 Reduced 3.92%
1,251 $303,000
Q4 2022

Jan 12, 2023

SELL
$229.03 - $291.01 $132,608 - $168,494
-579 Reduced 30.78%
1,302 $342,000
Q3 2022

Nov 22, 2022

BUY
$224.46 - $253.15 $33,669 - $37,972
150 Added 8.67%
1,881 $424,000
Q2 2022

Jul 15, 2022

BUY
$230.71 - $256.74 $10,151 - $11,296
44 Added 2.61%
1,731 $421,000
Q1 2022

May 12, 2022

BUY
$219.27 - $242.57 $127,176 - $140,690
580 Added 52.39%
1,687 $408,000
Q4 2021

Feb 07, 2022

SELL
$198.88 - $227.6 $114,157 - $130,642
-574 Reduced 34.15%
1,107 $249,000
Q3 2021

Oct 12, 2021

BUY
$212.27 - $248.7 $849 - $994
4 Added 0.24%
1,681 $358,000
Q4 2020

Feb 10, 2021

BUY
$216.38 - $257.67 $2,380 - $2,834
11 Added 0.66%
1,677 $386,000
Q2 2020

Aug 13, 2020

BUY
$197.81 - $242.74 $18,791 - $23,060
95 Added 6.05%
1,666 $393,000
Q1 2020

May 11, 2020

BUY
$182.24 - $241.7 $14,761 - $19,577
81 Added 5.44%
1,571 $319,000
Q4 2019

Feb 04, 2020

SELL
$189.21 - $243.2 $756 - $972
-4 Reduced 0.27%
1,490 $359,000
Q3 2019

Nov 06, 2019

BUY
$174.11 - $208.62 $696 - $834
4 Added 0.27%
1,494 $289,000
Q2 2019

Aug 09, 2019

BUY
$166.7 - $195.41 $18,503 - $21,690
111 Added 8.05%
1,490 $275,000
Q1 2019

May 08, 2019

BUY
$180.87 - $203.88 $18,087 - $20,388
100 Added 7.82%
1,379 $262,000
Q3 2018

Nov 09, 2018

SELL
$185.29 - $208.89 $37,058 - $41,778
-200 Reduced 13.52%
1,279 $265,000
Q2 2018

Aug 03, 2018

SELL
$166.05 - $186.51 $1,328 - $1,492
-8 Reduced 0.54%
1,479 $273,000
Q4 2017

Feb 09, 2018

SELL
$168.79 - $188.59 $2,194 - $2,451
-13 Reduced 0.87%
1,487 $259,000
Q3 2017

Oct 31, 2017

BUY
$167.29 - $191.0 $250,935 - $286,500
1,500
1,500 $280,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Smith Chas P & Associates Pa Cpas Portfolio

Follow Smith Chas P & Associates Pa Cpas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith Chas P & Associates Pa Cpas, based on Form 13F filings with the SEC.

News

Stay updated on Smith Chas P & Associates Pa Cpas with notifications on news.